Evolving Practices for Myelodysplastic Syndromes (MDS): Highlights from ASH 2024 and Beyond - Episode 2
Panelists discuss how the primary therapeutic goals for patients with intermediate- to high-risk myelodysplastic syndromes (MDS) focus on extending survival and modifying disease course through intensive treatments like hypomethylating agents or stem cell transplantation while addressing unique challenges such as treatment resistance, poor response durability, and limited options after hypomethylating agents failure.
Video content above is prompted by the following: